SG11201803816RA - Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease - Google Patents
Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart diseaseInfo
- Publication number
- SG11201803816RA SG11201803816RA SG11201803816RA SG11201803816RA SG11201803816RA SG 11201803816R A SG11201803816R A SG 11201803816RA SG 11201803816R A SG11201803816R A SG 11201803816RA SG 11201803816R A SG11201803816R A SG 11201803816RA SG 11201803816R A SG11201803816R A SG 11201803816RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- receptor
- bristol
- new jersey
- pennington
- Prior art date
Links
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 title abstract 8
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 title abstract 6
- 208000019622 heart disease Diseases 0.000 title abstract 3
- 101710109169 Formyl peptide receptor 2 Proteins 0.000 title abstract 2
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 101150103751 FPR2 gene Proteins 0.000 title 1
- 101100446655 Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) FKBP2 gene Proteins 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803816RA true SG11201803816RA (en) | 2018-06-28 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803816RA SG11201803816RA (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (https=) |
| EP (1) | EP3380091A1 (https=) |
| JP (1) | JP2018538367A (https=) |
| KR (1) | KR20180081528A (https=) |
| CN (1) | CN108348479A (https=) |
| AU (1) | AU2016359463A1 (https=) |
| BR (1) | BR112018010155A8 (https=) |
| CA (1) | CA3006291A1 (https=) |
| EA (1) | EA201891007A1 (https=) |
| IL (1) | IL259468A (https=) |
| MX (1) | MX2018005756A (https=) |
| SG (1) | SG11201803816RA (https=) |
| WO (1) | WO2017091496A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492167C2 (ru) * | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| KR101905927B1 (ko) * | 2010-11-17 | 2018-10-08 | 이도르시아 파마슈티컬스 리미티드 | 가교된 스피로［２．４］헵탄 에스테르 유도체 |
| CA2871334A1 (en) * | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| EP3414227B1 (en) * | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| US10676431B2 (en) * | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180325869A1 (en) | 2018-11-15 |
| KR20180081528A (ko) | 2018-07-16 |
| CA3006291A1 (en) | 2017-06-01 |
| EP3380091A1 (en) | 2018-10-03 |
| BR112018010155A8 (pt) | 2019-02-26 |
| WO2017091496A1 (en) | 2017-06-01 |
| MX2018005756A (es) | 2018-08-01 |
| CN108348479A (zh) | 2018-07-31 |
| IL259468A (en) | 2018-07-31 |
| JP2018538367A (ja) | 2018-12-27 |
| EA201891007A1 (ru) | 2018-11-30 |
| AU2016359463A1 (en) | 2018-07-12 |
| BR112018010155A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408261UA (en) | Syringe | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |